Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization.
Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization.
复制标题
DOI：
10.2147/opth.s30907
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Yoshimura N
中科院分区：
文献类型：
--
作者：
Ellabban AA;Tsujikawa A;Ogino K;Ooto S;Yamashiro K;Oishi A;Yoshimura N
研究雷尼单抗治疗脉络膜新生血管（CNV）时脉络膜厚度的变化。前瞻性病例系列。这项前瞻性研究包括60名cnv患者的60只眼睛，在初始加载阶段后使用按需方案进行雷尼单抗玻璃体内注射。研究的眼睛包括20例年龄相关性黄斑变性（AMD）， 20例息肉样脉络膜血管病变（PCV）和20例近视CNV。在AMD和PCV的眼睛中，使用光学相干断层扫描测量中央凹的脉络膜厚度，使用增强深度成像。在近视CNV中，使用标准光学相干断层扫描测量脉络膜厚度，不使用增强深度成像技术。雷尼单抗治疗后，视网膜中央厚度明显降低（P < 0.001），视力明显改善（P < 0.001）。加载后1个月（165.2±107.8 μm, P = 0.120）和期末检查（164.8±107.7 μm, P = 0.115）中央脉络膜厚度（167.2±108.3 μm）无显著变化。在基线时，AMD患者的视网膜中央厚度明显大于PCV患者（P = 0.005）或高度近视患者（P = 0.029）。然而，近视CNV的中央脉络膜厚度明显薄于AMD （P < 0.001）或PCV （P < 0.001）。在每种类型的疾病中，雷尼单抗治疗没有显著改变中央脉络膜厚度。雷尼单抗对脉络膜厚度的影响很小，如果有的话。
To study changes in choroidal thickness with ranibizumab treatment for choroidal neovascularization (CNV). Prospective case series. This prospective study consisted of 60 CNV-affected eyes of 60 patients treated with intravitreal injections of ranibizumab using an on-demand protocol after an initial loading phase. The eyes studied included 20 with age-related macular degeneration (AMD), 20 with polypoidal choroidal vasculopathy (PCV), and 20 with myopic CNV. In the eyes with AMD and PCV, choroidal thickness at the fovea was measured with optical coherence tomography using enhanced depth imaging. In eyes with myopic CNV, the choroidal thickness was measured using standard optical coherence tomography without the enhanced depth imaging technique. With ranibizumab treatment, central retinal thickness decreased significantly (P < 0.001) and visual acuity improved significantly (P < 0.001). However, central choroidal thickness (167.2 ± 108.3 μm) showed no significant change at 1 month after the loading phase (165.2 ± 107.8 μm, P = 0.120) or at final examination (164.8 ± 107.7 μm, P = 0.115). At baseline, central retinal thickness in eyes with AMD was significantly greater that those with PCV (P = 0.005) or high myopia (P = 0.029). However, central choroidal thickness in eyes with myopic CNV was significantly thinner than in eyes with AMD (P < 0.001) or PCV (P < 0.001). In each type of disease, there was no significant change in central choroidal thickness with ranibizumab treatment. The effect of ranibizumab on the choroidal thickness is minimal, if any.